Clinical Trial Search

Primary: Change From Baseline of Total Cholesterol After 90 Days — -0.57; -1.09 mmol/L — p=0.042

Primary: Cardiovascular Disease Risk Factors — 3; 4; 5; 7 participants

Primary: Change in FMD% — -0.06; -0.11; -0.06 FMD percent — p=0.864

Primary: Cutaneous Blood Flow Response to Local Heating of the Skin. — 68; 70 percent change in mean skin blood flow

Primary: Systolic Blood Pressure — 127.0; 126.5 mm Hg — p=0.588

Primary: Vascular Endothelial Function — -294.4; -152.9; -102.9; -361.6 %FMD*min

Primary: Eating Habits Confidence Survey — 4.2; 4.5 units on a scale

Primary: Number of Participants With Total Cardiovascular Disease (CVD) Events — 410; 456; 429; 437 Participants

Primary: Participation in Cardiac Rehabilitation — 231; 252 Participants — p=0.80

Primary: Change From Baseline in Insulin Sensitivity at 4 Weeks — 0.28; -0.29 Calculated Ratio - No units

Primary: Vascular Endothelial Function — -307; -34.8; -36.8; -110 %*min

Primary: Number of Participants With Visit to a Cardiology Specialist From Cohort — 283 Participants

Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale

Primary: Compare Change in Platelet Aggregation as Measured by Adenosine Diphosphate (ADP) Between PGJ and Placebo — 1.59; -12.3 percent

Primary: Carotid-femoral Pulse Wave Velocity (CFPWV) — 831.3; 785.1; 538.0; 839.6 cm/sec

Primary: Difference in Mean Change in Prime Diet Quality Score Between Groups Between Months 0 and 6 — 1.22 Units on a scale

Primary: Vascular Endothelial Function — -195.9; -6.181; -5.629 %*min

Primary: New Participation in MOVE! (Among Women Aged 65 and Older) — 1.09 Odds Ratio — p=.003

Primary: Change in Lipidomic Profiles

Primary: Change in East Boston Memory Test Scores From Baseline to 24 Weeks, 48 Weeks, and 72 Weeks — 0.03; -0.02; 0.01; 0.05 score on a scale — p=.409

Primary: Change (Per Day) in Average Daily Steps From Baseline — 2.8; 2.9; -8.2; -1.2 Change (per day) in Average Daily Steps — p=0.973

Primary: Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke — 14.2; 20.8 percentage of annual rate of change

Primary: Global Framingham Risk Score — 11.5; 12.7; 9.9; 12.3 score on a scale

Primary: Flow-mediated Dilation (FMD) Percentage — 7.61; 8.27; 7.31 percentage of baseline dilation — p=0.88

Primary: Change in KAH Score for Children — 7.66; 3.76 units on a scale — p=<.001

Primary: Change in Hippocampal Volume — -15.4; -49.9 mm^3

Primary: Change From Baseline in Lipid Profile — 4.20; 3.37; -0.06 mg/dl

Primary: Predicted Annual Rate of Change in 10-year Risk of Fatal or Nonfatal Heart Attack or Stroke — -0.59; 1.66 annualized change in 10 year % cv risk — p=<0.05

Primary: Number of Participants Who Stated (by Self-report) That They Had Side Effects — 1; 0; 2; 1 participants

Primary: AIM 1: Change in Flow Mediated Dilation (FMD) (%) — -0.0012; 0.018; 0.014; 0.0053 percentage of arterial dilation change — p=0.943